SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) — Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay. Due to current labeling for …
The post Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML appeared first on ForexTV.
April 28, 2017 at 09:55PM
from Nasdaq NewsFeed
No comments:
Post a Comment